Home
Conditions
Multiple Myeloma

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,608 public trials 494 recruiting studies

Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma

NCT00999830

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: C.H.R.U. de Caen - Hôpital Bretonneau Caen, France

CHU Dijon Dijon, France

CHRU Lille Lille, France

Hôpital Dupuytren Limoges, France

View Trial Details

Completed

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01359657

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations: H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States

University Of Kansas Cancer Center And Medical Pavillion Westwood, Kansas, United States

Dana Faber Cancer Institute Boston, Massachusetts, United States

University Of Washington School Of Medicine Seattle, Washington, United States

View Trial Details

Completed

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

NCT00293384

Conditions: Adnexal Diseases, Blast Crisis, Blood Protein Disorders, +112 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Completed

Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors

NCT00618969

Conditions: Anemia, Anemia, Aplastic, Anemia, Hemolytic, +26 more
Locations: Arizona Cancer Center/University Medical Center Tucson, Arizona, United States

View Trial Details

Completed

Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)

NCT01352338

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Antonius Ziekenhuis Nieuwegein Nieuwegein, Utrecht, Netherlands

UMC Utrecht Utrecht, Netherlands

VU Medical Center Amsterdam, Netherlands

View Trial Details

Completed

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

NCT01413568

Conditions: Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Blood Protein Disorders, +36 more
Locations: University of Kansas Cancer Center Kansas City, Kansas, United States

Washington University School of Medicine St Louis, Missouri, United States

View Trial Details

Completed

Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

NCT00123773

Conditions: Adnexal Diseases, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations: Cross Cancer Institute Edmonton, Alberta, Canada

View Trial Details

Completed

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

NCT00975975

Conditions: Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Anemia, +47 more
Locations: Indiana University Cancer Center Indianapolis, Indiana, United States

View Trial Details

Completed

Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma

NCT01530594

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: King Faisal Specialist Hospital &Reseach Center Riyadh, Saudi Arabia

View Trial Details

Completed

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

NCT01094548

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Please Contact the Merck KGaA Communication Center Darmstadt, Germany

View Trial Details

Multiple Myeloma

Multiple Myeloma trial results

Related conditions